Table 5 Baseline characteristics of the treatment groups (per-protocol)

(n 33)

(n 37)

–

Age (years)

64.6 (8.2)

64.4 (6.0)

0.892

Sex (% female)

54.5

59.5

–

Weight (kg)

72.5 (61.7–80.2)

72.8 (63.3–84.2)

0.881

Height (m)

1.69 (0.10)

1.68 (0.08)

0.535

BMI (kg/m²)

24.8 (23.0–28.3)

25.4 (23.4–29.5)

0.582

Waist (cm)

90.8 (81.5–100.3)

89.8 (81.5–105.1)

0.539

Hip (cm)

102.0 (97.8–107.3)

102.1 (99.6–109.1)

0.844

Waist:hip

0.88 (0.09)

0.90 (0.10)

0.455

Systolic BP (mmHg)

129.2 (20.0)

127.2 (21.1)

0.694

Diastolic BP (mmHg)

76.0 (9.2)

75.2 (11.5)

0.765

Plasma total 25(OH)D (nmol/L)

59.6 (49.3–73.5)

58.8 (37.6–65.4)

0.500

Serum homocysteine (µmol/L)

10.5 (9.6–12.6)

11.6 (10.0–14.8)

0.035

Serum folate (nmol/L)

18.2 (14.1–24.0)

15.5 (12.5–21.6)

0.177

Serum vitamin B12 (pmol/L)

344 (243–439)

310 (246–413)

0.374

Plasma PLP (vitamin B6 (nmol/L)

63.9 (49.1–79.8)

59.4 (45.5–79.4)

0.388

Riboflavin (EGRac)

1.28 (1.22–1.34)

1.34 (1.25–1.41)

0.088